Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWirawan, Jeong*
dc.contributor.authorSnell, Greg I.*
dc.contributor.authorLevvey, Bronwyn J.*
dc.contributor.authorWestall, Glen P.*
dc.contributor.authorMorrissey, C. Orla*
dc.contributor.authorIvulich, Steven*
dc.contributor.authorNeoh, Chin Fen*
dc.contributor.authorSlavin, Monica A.*
dc.contributor.authorKong, David C. M.*
dc.description.abstractThis study describes the clinical outcomes and therapeutic drug monitoring (TDM) following posaconazole suspension pre-emptive therapy in lung transplant (LTx) recipients. This was a single-centre, retrospective cohort study evaluating posaconazole suspension pre-emptive therapy in LTx recipients between January 2009 and December 2015. Forty-two LTx recipients were prescribed posaconazole suspension pre-emptively. Aspergillus fumigatus was the most commonly isolated fungal organism. Of the patients receiving posaconazole suspension as the initial antifungal post-LTx, 93% had eradication of colonization at 6 months after commencing therapy. In contrast, only 61% had eradication of fungal colonization when posaconazole suspension was administered following initial therapy with voriconazole. Posaconazole suspension appeared to be well tolerated, although one case was curtailed following concern about abnormal liver function and another due to nausea/vomiting. TDM was performed in 37 patients. The initial median (IQR) trough plasma concentration (Cmin) following 400 mg twice-daily posaconazole suspension was 0.78 (0.46–1.19) mg/L. Doses beyond 800 mg daily did not appear to result in a higher median Cmin Early initiation of posaconazole suspension pre-emptive therapy in LTx recipients appears to be well tolerated and may potentially afford favourable clinical outcomes.en_US
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2017-09-28T04:44:54Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2017-10-10T03:22:33Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2017-10-10T03:22:33Z (GMT). No. of bitstreams: 0 Previous issue date: 2017en
dc.titleClinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: the Alfred's experience.en_US
dc.typeJournal Articleen_US
dc.bibliographicCitation.titleThe Journal of Antimicrobial Chemotherapyen_US
dc.subject.healththesaurusANTIFUNGAL AGENTSen_US
dc.subject.healththesaurusASPERGILLUS FUMIGATUSen_US
dc.subject.healththesaurusDRUG MONITORINGen_US
dc.subject.healththesaurusLUNG TRANSPLANTATIONen_US
dc.subject.healththesaurusRETROSPECTIVE STUDIESen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.